Novartis shares drop after drug trial fails

Novartis shares fell after its cholesterol drug pelacarsen missed its primary goal in a late-stage study. The setback increases pressure on upcoming pipeline data for the Swiss drugmaker.

Xurve View
Insights:
FILE PHOTO: A view of the Novartis booth and logo at the BIO International Convention 2026, a meeting of pharmaceutical and biotechnology leaders in San Diego, California, U.S. June 23, 2026. REUTERS/Mike Blake/File Photo

NOVARTIS AG-REG shares fell 3.3% on Monday morning after its experimental cholesterol drug failed a key clinical trial. The setback casts doubt on a therapeutic approach targeting Lp(a) proteins. The failure increases pressure on upcoming pipeline data for the Switzerland-based drugmaker.